Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin Biotech, Inc. is based in Houston, TX.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-21.76M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -278.80% |
| Return on Assets (Trailing 12 Months) | -100.11% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.35 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.35 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.77 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.69 |
| Earnings per Share (Most Recent Fiscal Year) | $-6.32 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 14.13M |
| Free Float | 13.86M |
| Market Capitalization | $4.16M |
| Average Volume (Last 20 Days) | 3.42M |
| Beta (Past 60 Months) | 1.56 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 15.52% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |